§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇨🇴Colombia	🇺🇸United States	🇪🇺European Union
Authority & dossier
Regulatory authority	INVIMA	FDA	EMA
English submissions	No	Yes	Yes
CTD accepted	Yes	Yes	Yes
eCTD accepted	No	Yes	Yes
Reliance pathway	Available	None	Available
Reference agencies	FDA, EMA, MHRA, Swissmedic +4	—	—
Lead pathway (timeline & fees) — Registro Sanitario — Medicamento de Síntesis Química (Standard) · New Drug Application — 505(b)(1) · Centralised Procedure
Pathway name	Registro Sanitario — Medicamento de Síntesis Química (Standard)	New Drug Application — 505(b)(1)	Centralised Procedure
Approval timeline	240–480 days	304–365 days	210–277 days
Application fee	COP 25,000,000	USD 4,310,002	EUR 358,800
Annual renewal	COP 0	USD 416,734	EUR 122,500
Local representative	Required	Not required	Required
Local manufacturing	Not required	Not required	Not required
GMP inspection	Required	Required	Required
MAH & local presence
Local entity required	Yes	No	Yes
Local responsible person	Yes	Yes	Yes
RP role	A Director Técnico (registered químico farmacéutico or equivalent) must be designated for each establishment per Decree 677/1995. A Responsable de Farmacovigilancia must be designated under Resolución 2024015321 of 2024 with responsibility for ICSR submission and periodic safety reports.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.	Qualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).
Accelerated pathways
Designations available	2 designations	6 designations	6 designations
Examples	Autorización Excepcional por Emergencia, Medicamento Vital No Disponible (MVND)	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3	Accelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3
Post-approval lifecycle
Variations framework	Variations classified by INVIMA into modificaciones de seguridad y eficacia (major, requiring Sala Especializada review), modificaciones administrativas (minor, requiring INVIMA approval) and notificaciones. Decree 843 of 2016 simplified renewal and several modification procedures for chemical-synthesis medicines.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.	Commission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.
Renewal cycle	Registro Sanitario for chemical-synthesis medicines valid for 10 years; biologics typically 5 years. Renewal application (renovación) must be filed before expiry; Decree 843 of 2016 simplified the renewal process (presumed continuity for compliant holders).	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.	Initial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.
Pharmacovigilance	Pharmacovigilance regulated by Resolución 2024015321 of 2024 (replacing parts of Resolución 9455 of 2004). MAHs must operate a national PV system, designate a Responsable de Farmacovigilancia, submit ICSRs (15-day for serious unlisted), file Periodic Safety Update Reports per ICH E2C(R2), and maintain Risk Management Plans for new molecules and biologics. Reports filed via INVIMA's e-Reporting Industria platform.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.	Comprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.
Unlicensed access
Named Patient Supply	Available	Available	Available
Compassionate Use	Available	Available	Available
Emergency Import	Available	Available	Available
Parallel Import	Not permitted	Not permitted	Permitted
Clinical trials
CTA approval	Required	Required	Required
Ethics approval	Yes	Yes	Yes
CTA timeline	120–180 days	30–30 days	60–106 days
GCP standard	INVIMA Resolución 2378 of 2008 — Buenas Prácticas Clínicas (aligned with ICH-GCP E6)	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56	ICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025
Pricing & reimbursement
Price regulation	Regulated	Free pricing	Regulated
Reference pricing	Yes	No	Yes
HTA required	Yes	No	Yes
HTA body	Instituto de Evaluación Tecnológica en Salud (IETS)	ICER (Institute for Clinical and Economic Review) — independent, non-binding	EU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

ColombiaINVIMA
United StatesFDA
European UnionEMA

English submissions

ColombiaNo
United StatesYes
European UnionYes

CTD accepted

ColombiaYes
United StatesYes
European UnionYes

eCTD accepted

ColombiaNo
United StatesYes
European UnionYes

Reliance pathway

ColombiaAvailable
United StatesNone
European UnionAvailable

Reference agencies

ColombiaFDA, EMA, MHRA, Swissmedic +4
United States—
European Union—

Lead pathway (timeline & fees) — Registro Sanitario — Medicamento de Síntesis Química (Standard) · New Drug Application — 505(b)(1) · Centralised Procedure

Pathway name

ColombiaRegistro Sanitario — Medicamento de Síntesis Química (Standard)
United StatesNew Drug Application — 505(b)(1)
European UnionCentralised Procedure

Approval timeline

Colombia240–480 days
United States304–365 days
European Union210–277 days

Application fee

ColombiaCOP 25,000,000
United StatesUSD 4,310,002
European UnionEUR 358,800

Annual renewal

ColombiaCOP 0
United StatesUSD 416,734
European UnionEUR 122,500

Local representative

ColombiaRequired
United StatesNot required
European UnionRequired

Local manufacturing

ColombiaNot required
United StatesNot required
European UnionNot required

GMP inspection

ColombiaRequired
United StatesRequired
European UnionRequired

MAH & local presence

Local entity required

ColombiaYes
United StatesNo
European UnionYes

Local responsible person

ColombiaYes
United StatesYes
European UnionYes

RP role

ColombiaA Director Técnico (registered químico farmacéutico or equivalent) must be designated for each establishment per Decree 677/1995. A Responsable de Farmacovigilancia must be designated under Resolución 2024015321 of 2024 with responsibility for ICSR submission and periodic safety reports.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
European UnionQualified Person Responsible for Pharmacovigilance (QPPV) — must reside and operate in the EU/EEA — is responsible for the establishment and maintenance of the pharmacovigilance system. A Qualified Person (QP) in the EU/EEA performs batch certification under Article 51 of Directive 2001/83/EC. Local Contact Person for pharmacovigilance required in each Member State where the product is marketed (since 2012 GVP).

Accelerated pathways

Designations available

Colombia2 designations
United States6 designations
European Union6 designations

Examples

ColombiaAutorización Excepcional por Emergencia, Medicamento Vital No Disponible (MVND)
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
European UnionAccelerated Assessment, Conditional Marketing Authorisation, Authorisation under Exceptional Circumstances +3

Post-approval lifecycle

Variations framework

ColombiaVariations classified by INVIMA into modificaciones de seguridad y eficacia (major, requiring Sala Especializada review), modificaciones administrativas (minor, requiring INVIMA approval) and notificaciones. Decree 843 of 2016 simplified renewal and several modification procedures for chemical-synthesis medicines.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
European UnionCommission Regulation (EC) 1234/2008 establishes four categories: Type IA (minor — Do and Tell, 12-month notification), Type IAIN (minor — immediate notification), Type IB (minor — Tell, Wait, and Do, 30-day default), Type II (major — prior approval, 60–90 days), and Extensions (Annex I changes — full review). Worksharing procedures consolidate variations across multiple authorisations.

Renewal cycle

ColombiaRegistro Sanitario for chemical-synthesis medicines valid for 10 years; biologics typically 5 years. Renewal application (renovación) must be filed before expiry; Decree 843 of 2016 simplified the renewal process (presumed continuity for compliant holders).
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
European UnionInitial 5-year renewal — application 9 months before expiry. After the first renewal, MA is granted for unlimited duration unless the CHMP/NCA, on justified grounds relating to pharmacovigilance, decides on one additional 5-year renewal.

Pharmacovigilance

ColombiaPharmacovigilance regulated by Resolución 2024015321 of 2024 (replacing parts of Resolución 9455 of 2004). MAHs must operate a national PV system, designate a Responsable de Farmacovigilancia, submit ICSRs (15-day for serious unlisted), file Periodic Safety Update Reports per ICH E2C(R2), and maintain Risk Management Plans for new molecules and biologics. Reports filed via INVIMA's e-Reporting Industria platform.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
European UnionComprehensive PV framework under Directive 2010/84/EU and Regulation (EU) 1235/2010, codified in Good Pharmacovigilance Practices (GVP). Pharmacovigilance System Master File (PSMF) required. Periodic Safety Update Reports (PSURs) on EU-harmonised birth-date list. Risk Management Plans for all new MAs and significant variations. Suspected serious ADR reporting to EudraVigilance within 15 days. Black triangle (▼) for additional monitoring of selected products.

Unlicensed access

Named Patient Supply

ColombiaAvailable
United StatesAvailable
European UnionAvailable

Compassionate Use

ColombiaAvailable
United StatesAvailable
European UnionAvailable

Emergency Import

ColombiaAvailable
United StatesAvailable
European UnionAvailable

Parallel Import

ColombiaNot permitted
United StatesNot permitted
European UnionPermitted

Clinical trials

CTA approval

ColombiaRequired
United StatesRequired
European UnionRequired

Ethics approval

ColombiaYes
United StatesYes
European UnionYes

CTA timeline

Colombia120–180 days
United States30–30 days
European Union60–106 days

GCP standard

ColombiaINVIMA Resolución 2378 of 2008 — Buenas Prácticas Clínicas (aligned with ICH-GCP E6)
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
European UnionICH E6(R3) — Commission Regulation (EU) 2024/2748 transposing R3, applicable from 23 July 2025

Pricing & reimbursement

Price regulation

ColombiaRegulated
United StatesFree pricing
European UnionRegulated

Reference pricing

ColombiaYes
United StatesNo
European UnionYes

HTA required

ColombiaYes
United StatesNo
European UnionYes

HTA body

ColombiaInstituto de Evaluación Tecnológica en Salud (IETS)
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding
European UnionEU HTA Coordination Group (EUnetHTA legacy); national HTA bodies (NICE, HAS, G-BA/IQWiG, AIFA, AEMPS, etc.)